-
Subject Areas on Research
-
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.
-
A phase I/II study of the protease inhibitor indinavir in children with HIV infection.
-
A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.
-
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
-
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
-
Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents.
-
C2-symmetrical tetrahydroxyazepanes as inhibitors of glycosidases and HIV/FIV proteases.
-
Can the thymus win the battle against drug-resistant HIV?
-
Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.
-
Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.
-
Combination antiretroviral therapy.
-
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
-
Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.
-
Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.
-
Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy.
-
Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.
-
Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
-
Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease.
-
Development of a novel screen for protease inhibitors.
-
Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.
-
Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
-
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
-
Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation.
-
Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.
-
Frequency of atazanavir-associated leukocyturia development and renal function decline.
-
Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
-
High prevalence of PI resistance in patients failing second-line ART in Vietnam.
-
Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells.
-
Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
-
Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013.
-
Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages.
-
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
-
Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality.
-
Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.
-
Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells.
-
Lack of protease inhibitor resistance following treatment failure--too good to be true?
-
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
-
Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
-
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.
-
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
-
Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
-
Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.
-
Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview.
-
Molecular targets of anti-HIV-1 triterpenes.
-
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
-
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
-
Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.
-
Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.
-
Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.
-
Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children.
-
Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates.
-
Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.
-
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.
-
Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084.
-
Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
-
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
-
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
-
Taking HAART in HIVAN: will protease inhibitor sparing regimens alter renal outcome?
-
The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia.
-
The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation.
-
The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis.
-
Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.
-
Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007.
-
Transplantation in the HIV+ patient.
-
Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
-
Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.
-
Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.
-
Keywords of People